Palleon Pharmaceuticals
Biotechnology-Research
Website
Company Tagline
Clinical-stage biotech company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases
Industry Category
Business Keywords
Company Description
Palleon Pharmaceuticals is a leading biotechnology company dedicated to developing innovative Glyco-Immune Checkpoint inhibitors for cancer treatment. Leveraging its proprietary Convergence Platform, Palleon Pharmaceuticals integrates cutting-edge technologies and insights from globally recognized experts in glycoscience and human immunology, creating a novel and highly effective approach to combatting cancer. The company's primary address is 266 Second Ave, Waltham, Massachusetts 02451, US.
By targeting multiple immune cell types, Palleon Pharmaceuticals' Glyco-Immune Checkpoint inhibitors are designed to overcome resistance to first-generation immuno-oncology agents, paving the way for a broader spectrum of rational combination therapies in cancer treatment. While the initial focus is on oncology, the versatile Convergence Platform holds promising applications across various therapeutic areas, including infectious diseases, neurodegeneration, inflammation, and fibrosis. Palleon Pharmaceuticals is committed to advancing its pipeline and development programs, driving forward the next generation of immunotherapies.
Palleon Pharmaceuticals is poised for continued growth and innovation in the biotechnology sector. We invite the management team at Palleon Pharmaceuticals to enhance your company's visibility by creating a customized and exclusive company showcase and product listing on our platform.
Palleon Pharmaceuticals est une société de biotechnologie de premier plan dédiée au développement d'inhibiteurs de points de contrôle glyco-immunitaires innovants pour le traitement du cancer. Tirant parti de sa plateforme exclusive Convergence, Palleon Pharmaceuticals intègre des technologies de pointe et des connaissances d'experts de renommée mondiale en glycoscience et en immunologie humaine, créant une approche nouvelle et très efficace pour lutter contre le cancer. L'adresse principale de l'entreprise est 266 Second Ave, Waltham, Massachusetts 02451, États-Unis.
En ciblant plusieurs types de cellules immunitaires, les inhibiteurs de points de contrôle glyco-immunitaires de Palleon Pharmaceuticals sont conçus pour surmonter la résistance aux agents d'immuno-oncologie de première génération, ouvrant la voie à un éventail plus large de thérapies combinées rationnelles dans le traitement du cancer. Bien que l'objectif initial soit l'oncologie, la plateforme Convergence polyvalente offre des applications prometteuses dans divers domaines thérapeutiques, notamment les maladies infectieuses, la neurodégénérescence, l'inflammation et la fibrose. Palleon Pharmaceuticals s'engage à faire progresser son pipeline et ses programmes de développement, faisant progresser la prochaine génération d'immunothérapies.
Palleon Pharmaceuticals est sur le point de poursuivre sa croissance et son innovation dans le secteur de la biotechnologie. Nous invitons l'équipe de direction de Palleon Pharmaceuticals à améliorer la visibilité de votre entreprise en créant une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme.
Key Personnel / Employees
Compare Companies Side by Side
Compare Palleon Pharmaceuticals with 3 companies in Biotechnology-Research
| Comparison Field |
Palleon PharmaceuticalsMain Company |
Kyowa Kirin Internat...View Profile |
NKILT Therapeutics,...View Profile |
Molecule to MedicineView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 1995 | 2021 | 2015 |
|
Company Size
|
— | 501-1,000 | 2-10 | 11-50 |
|
City
|
Waltham, Massachusetts | Galashiels, Selkirkshire | Houston, Texas | Oxford, England |
|
Country
|
United States | United States | United Kingdom | |
|
Skills & Keywords
Comparing with main company
|
9 Total Skills
Biotechnology
Immuno-Oncology
Glyco-Immunology
Drug Development
Cancer Treatment
Immunotherapy
Pharmaceuticals
Clinical Development
Glyco-Immune Checkpoint Inhibitors
|
11 Total
1 Common
10 Unique
Match
11%
Common Skills:
Pharmaceuticals
Unique Skills:
Antibodies
Biopharmaceuticals
Central Nervous System
Drug Discovery
Hematology / Haematology
Nephrology
+4
|
9 Total
9 Unique
Unique Skills:
Cancer Research
Cell Therapy
Hematology
HLA-G
Immune Cell Engineering
Leukemia
+3
|
7 Total
2 Common
5 Unique
Match
22%
Common Skills:
Drug Development
Pharmaceuticals
Unique Skills:
Back Office Support for Virtual & Semi-VIrtual Companies & Teams
Commercialisation
Corporate Governance
Drug Discovery
Due Diligence & Expert Opinion Services
|
4
Total Companies1995
Oldest Founded2
Countries31
Unique SkillsSimilar Companies
Other organizations in the same industry
Life Science Cares Philadelphia
Biotechnology-ResearchA collective industry effort to fight poverty in Greater Philadelphia
NMDP BioTherapies
Biotechnology-ResearchEmpowering the discovery, development and delivery of next-generation therapies.
HiFe Plants
Biotechnology-ResearchWe help people meet their iron requirements by providing biofortified plant foods and supplements.
Baruch S. Blumberg Institute
Biotechnology-ResearchThe translational research and educational arm of the worldwide Hepatitis B Foundation, located in D...
Alternative Company Names
This company is also known as